Dibekacin is an aminoglycoside antibiotic marketed in Japan L5623.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Furosemide | Furosemide may increase the ototoxic activities of Dibekacin. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Dibekacin. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dibekacin. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Dibekacin. |
| Cefepime | The risk or severity of ototoxicity and nephrotoxicity can be increased when Cefepime is combined with Dibekacin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Quinisocaine. |
| Cisatracurium | Dibekacin may increase the neuromuscular blocking activities of Cisatracurium. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Dibekacin. |
| Capecitabine | Capecitabine may increase the nephrotoxic activities of Dibekacin. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Dibekacin is combined with Olsalazine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Dibekacin. |
| Oxaliplatin | The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Dibekacin. |
| DaxibotulinumtoxinA | Dibekacin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Inotersen | The risk or severity of nephrotoxicity can be increased when Inotersen is combined with Dibekacin. |